Skip to main content

Table 6 Bivariate Analysis Association between Comorbidities and SIBO

From: The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience

Variables

SIBO, n (%)

Total

p value

PR

CI 95%

Yes

No

DM, n (%)

 Yes

46 (38.3)

74 (61.7)

120 (100)

0.068

2.141

0.935–4.902

 No

9 (22.5)

31 (77.5)

40 (100)

   

Dyslipidemia, n (%)

 Yes

43 (33.3)

86 (66.7)

129 (100)

0.571

0.792

0.352–1.780

 No

12 (38.7)

19 (61.3)

31 (100)

   

Obesity, n (%)

 Yes

34 (31.8)

73 (68.2)

107 (100)

0.325

0.710

0.358–1.407

 No

21 (39.6)

21 (60.4)

53 (100)

   

Metabolic Syndrome, n (%)

 Yes

42 (34.4)

80 (65.6)

122 (100)

0.980

1.010

0.469–2.174

 No

13 (34.2)

25 (65.8)

38 (100)

   

Central Obesity, n (%)

 Yes

46 (30.9)

103 (69.1)

149 (100)

0.001

0.099

0.021–0.478

 No

9 (81.8)

2 (18.2)

11 (100)

   
  1. SIBO Small Intestinal Bacterial Overgrowth, DM Diabetes Mellitus, PR Prevalence Ratio, CI Confidence Interval